Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies.
April-Monn SL, Kirchner P, Detjen K, Bräutigam K, Trippel MA, Grob T, Statzer C, Maire RS, Kollàr A, Chouchane A, Kunze CA, Horst D, Sadowski MC, Schrader J, Marinoni I, Wiedenmann B, Perren A. April-Monn SL, et al. Among authors: horst d. NPJ Precis Oncol. 2024 Mar 1;8(1):59. doi: 10.1038/s41698-024-00549-2. NPJ Precis Oncol. 2024. PMID: 38429350 Free PMC article.
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma.
Jank P, Leichsenring J, Kolb S, Hoffmann I, Bischoff P, Kunze CA, Dragomir MP, Gleitsmann M, Jesinghaus M, Schmitt WD, Kulbe H, Sers C, Stenzinger A, Sehouli J, Braicu IE, Westhoff C, Horst D, Denkert C, Gröschel S, Taube ET. Jank P, et al. Among authors: horst d. J Ovarian Res. 2023 Jul 31;16(1):150. doi: 10.1186/s13048-023-01239-6. J Ovarian Res. 2023. PMID: 37525239 Free PMC article.
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I, Dragomir MP, Monjé N, Keunecke C, Kunze CA, Schallenberg S, Marchenko S, Schmitt WD, Kulbe H, Sehouli J, Braicu IE, Jank P, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Sers C, Bischoff P, Taube ET. Hoffmann I, et al. Among authors: horst d. Neoplasia. 2023 Oct;44:100934. doi: 10.1016/j.neo.2023.100934. Epub 2023 Sep 11. Neoplasia. 2023. PMID: 37703626 Free PMC article.
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S, Hoffmann I, Monjé N, Dragomir MP, Jank P, Bischoff P, Keunecke C, Pohl J, Kunze CA, Marchenko S, Schmitt WD, Kulbe H, Sers C, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Taube ET. Kolb S, et al. Among authors: horst d. Hum Pathol. 2023 Nov;141:158-168. doi: 10.1016/j.humpath.2023.09.001. Epub 2023 Sep 22. Hum Pathol. 2023. PMID: 37742945 Free article.
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
Wasilewski D, Onken J, Höricke P, Bukatz J, Murad S, Früh A, Shaked Z, Misch M, Kühl A, Klein O, Ehret F, Kaul D, Radbruch H, Capper D, Vajkoczy P, Horst D, Frost N, Bischoff P. Wasilewski D, et al. Among authors: horst d. J Neurooncol. 2024 Mar;167(1):155-167. doi: 10.1007/s11060-024-04590-w. Epub 2024 Feb 15. J Neurooncol. 2024. PMID: 38358406 Free PMC article.
Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas.
Müller JH, Plage H, Elezkurtaj S, Mandelkow T, Huang Z, Lurati MCJ, Raedler JB, Debatin NF, Vettorazzi E, Samtleben H, Hofbauer S, Furlano K, Neymeyer J, Goranova I, Ralla B, Weinberger S, Horst D, Roßner F, Schallenberg S, Marx AH, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Lennartz M, Minner S, Simon R, Sauter G, Zecha H, Schlomm T, Bady E. Müller JH, et al. Among authors: horst d. Front Oncol. 2024 Jan 12;13:1342367. doi: 10.3389/fonc.2023.1342367. eCollection 2023. Front Oncol. 2024. PMID: 38282671 Free PMC article.
PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
Plage H, Furlano K, Hofbauer S, Weinberger S, Ralla B, Franz A, Fendler A, de Martino M, Roßner F, Elezkurtaj S, Kluth M, Lennartz M, Blessin NC, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Zecha H, Minner S, Simon R, Sauter G, Weischenfeldt J, Klatte T, Schlomm T, Horst D, Schallenberg S. Plage H, et al. Among authors: horst d. BMC Urol. 2024 Apr 24;24(1):96. doi: 10.1186/s12894-024-01482-z. BMC Urol. 2024. PMID: 38658905 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36335272
361 results